When cardiotoxicity demonstrated in Cardio-oncology is investigated in other contexts: Research into the cardiovascular effects of antiangiogenic drugs used in ophthalmology
Saved in:
| Main Author: | Júlia Cristina Toste |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Revista Portuguesa de Cardiologia |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0870255124003263 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
AI and Smart Devices in Cardio-Oncology: Advancements in Cardiotoxicity Prediction and Cardiovascular Monitoring
by: Luiza Camelia Nechita, et al.
Published: (2025-03-01) -
Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology
by: Iacob-Daniel Goje, et al.
Published: (2025-05-01) -
Challenges in the implementation of cardio-oncology trials: lessons learnt from investigating statins in the prevention of anthracycline cardiotoxicity
by: John Lee, et al.
Published: (2024-12-01) -
Telehealth consultations in cardio-oncology
by: V. I. Potievskaya, et al.
Published: (2022-02-01) -
Impact of a cardio‐oncology unit on prevention of cardiovascular events in cancer patients
by: Alessandra Cuomo, et al.
Published: (2022-06-01)